Active-State RAS Inhibitor
Solid tumors with broad KRAS mutations (e.g., G12D, G12V)
Key Facts
About BridgeBio Oncology Therapeutics
BridgeBio Oncology Therapeutics (BBOT) is a focused, public subsidiary of BridgeBio Pharma, established to conquer RAS-driven cancers through a novel, dual-pathway inhibition strategy. The company's mission is to translate deep biological insights into therapies that directly inhibit the active, GTP-bound state of RAS mutants and the PI3Kα pathway, a key resistance mechanism. Its strategy leverages the operational and financial infrastructure of its parent company to advance a targeted pipeline aimed at significant markets in pancreatic, colorectal, and lung cancers. While still in early clinical stages, BBOT represents a scientifically rigorous contender in the rapidly evolving post-KRAS G12C inhibitor landscape.
View full company profile